314 related articles for article (PubMed ID: 11918726)
1. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
De Vriese AS; Verbeke F; Schrijvers BF; Lameire NH
Kidney Int; 2002 Apr; 61(4):1199-209. PubMed ID: 11918726
[TBL] [Abstract][Full Text] [Related]
2. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
3. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?
Thambyrajah J; Landray MJ; McGlynn FJ; Jones HJ; Wheeler DC; Townend JN
Circulation; 2000 Aug; 102(8):871-5. PubMed ID: 10952955
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.
Qin X; Huo Y; Xie D; Hou F; Xu X; Wang X
Clin Nutr; 2013 Oct; 32(5):722-7. PubMed ID: 23313356
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
7. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
8. Folate, homocysteine, endothelial function and cardiovascular disease.
Moat SJ; Lang D; McDowell IF; Clarke ZL; Madhavan AK; Lewis MJ; Goodfellow J
J Nutr Biochem; 2004 Feb; 15(2):64-79. PubMed ID: 14972346
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
Righetti M; Serbelloni P; Milani S; Ferrario G
Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid.
Chiarello PG; Vannucchi MT; Moysés Neto M; Vannucchi H
Int J Vitam Nutr Res; 2003 Nov; 73(6):431-8. PubMed ID: 14743547
[TBL] [Abstract][Full Text] [Related]
11. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease.
Hyndman ME; Manns BJ; Snyder FF; Bridge PJ; Scott-Douglas NW; Fung E; Parsons HG
Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627
[TBL] [Abstract][Full Text] [Related]
12. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
[TBL] [Abstract][Full Text] [Related]
13. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
Clarke R; Armitage J
Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
[TBL] [Abstract][Full Text] [Related]
14. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease.
Stam F; van Guldener C; Ter Wee PM; Jakobs C; de Meer K; Stehouwer CD
Kidney Int; 2005 Jan; 67(1):259-64. PubMed ID: 15610249
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine and endothelial function in human studies.
Moat SJ; McDowell IF
Semin Vasc Med; 2005 May; 5(2):172-82. PubMed ID: 16047269
[TBL] [Abstract][Full Text] [Related]
16. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
17. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
[TBL] [Abstract][Full Text] [Related]
18. Variations in the lipid profile of patients with chronic renal failure, treated with folic acid.
de Gómez Dumm NT; Giammona AM; Touceda LA
Int J Vitam Nutr Res; 2003 May; 73(3):215-20. PubMed ID: 12847999
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine, folate, and cardiovascular disease.
Ward M
Int J Vitam Nutr Res; 2001 May; 71(3):173-8. PubMed ID: 11582839
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine-lowering therapy in renal disease.
Austen SK; Coombes JS; Fassett RG
Clin Nephrol; 2003 Dec; 60(6):375-85. PubMed ID: 14690253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
